Improving Childhood Immunization Service Delivery in Cameroon: A Synthesis of Caregiver Experiences and Recommendations.

Background/objectives: A "people-centered" approach is one of the core principles of the Immunization Agenda (IA) 2030 and emphasizes the need for services to be organized around the needs and expectations of individuals and the community. A better understanding of the immunization experience from the client's perspective is key to guiding the design of policies and interventions aimed at improving immunization delivery and coverage. This study provides a synthesis of the immunization experiences of children's caregivers in Cameroon, highlighting potential barriers for timely and complete immunization.

Improving the ONE HEALTH approach: a lesson from SARS-CoV-2 pandemic.

The emergence of SARS-CoV-2 has underscored the critical need to enhance the ONE HEALTH approach which recognizes the interconnectedness of human, animal, and environmental health. In this review we report on various animal species that were infected by SARS-CoV-2 virus during the pandemic with the aim to contribute to the One Health approach. The SARS-CoV-2 pandemic has highlighted the devastating consequences of zoonotic diseases such as COVID19 and has reiterated the critical role that the health of wildlife, domestic animals, and the environment plays in human health.

Development and characterization of high-throughput serological assays to measure magnitude and functional immune response against Paratyphi A in human samples.

Typhoid and Paratyphoid fever cause a global health burden, especially for the children of Southern Asia. The impact of the disease is further exacerbated by the dramatic increase of antimicrobial resistance. While vaccines against Typhi have been developed and successfully introduced, an effective vaccine targeting Paratyphi A is still lacking.

A validated and standardized pseudotyped microneutralization assay as a safe and powerful tool to measure LASSA virus neutralising antibodies for vaccine development and comparison.

Background: Over the past few decades, World Health Organization (WHO) has made massive efforts to promote the development of a vaccine against Lassa virus (LASV), one of the top ten priority pathogens for research and development under the WHO R&D Blueprint for Emerging Infections. To date, several vaccines are at different stages of development. In this scenario, a validated and standardised assay to measure LASV neutralising antibodies is urgently needed for vaccine development and comparison.